Combo Therapy Approved for Endometrial Cancer
Reuters
June 17, 2024
The U.S. Food and Drug Administration has approved a combination of the cancer drug Imfinzi and chemotherapy for adult patients with primary, advanced, or recurrent endometrial cancer that is mismatch repair deficient.
This decision follows a late-stage trial showing that Imfinzi, when used with chemotherapy drugs carboplatin and paclitaxel and followed by Imfinzi alone, reduced the risk for disease progression or death by 58% in specific endometrial cancer patients compared to chemotherapy alone.
"Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease," said Dave Fredrickson, executive vice-president of the oncology business unit at AstraZeneca.
Endometrial cancer is the fourth most prevalent cancer among women in the U.S., affecting over 66,000 patients and causing nearly 12,000 deaths in 2022.